Cardiac Dysfunction Assessment
Cardiac Dysfunction Assessment - Related Videos
07:32
Analysis of Cardiac Contractile Dysfunction and Ca2+ Transients in Rodent Myocytes
0 Views •
Cited by 2 •
2022
A set of protocols are presented that describe the measurement of contractile function via sarcomere length detection along with calcium (Ca2+) transient measurement in isolated rat myocytes. The application of this approach for studies in animal models of heart failure is also included.
08:35
Oxygenation-sensitive Cardiac MRI with Vasoactive Breathing Maneuvers for the Non-invasive Assessment of Coronary Microvascular Dysfunction
0 Views •
Cited by 16 •
2022
The assessment of microvascular function by oxygenation-sensitive cardiac magnetic resonance imaging in combination with vasoactive breathing maneuvers is unique in its ability to assess rapid dynamic changes in myocardial oxygenation in vivo and, thus, may serve as a critically important diagnostic technique for coronary vascular function.
11:10
Respirometric Oxidative Phosphorylation Assessment in Saponin-permeabilized Cardiac Fibers
0 Views •
Cited by 32 •
2011
Saponin-permeabilized fiber preparation in conjunction with respirometric oxidative phosphorylation analysis provides integrative assessment of mitochondrial function. Mitochondrial respiration in physiological and pathological states can reflect various regulatory influences including mitochondrial interactions, morphology and biochemistry.
05:04
In vitro Assessment of Cardiac Reprogramming by Measuring Cardiac Specific Calcium Flux with a GCaMP3 Reporter
0 Views •
Cited by 4 •
2022
We describe here, the establishment and application of an Tg(Myh6-cre)1Jmk/J /Gt(ROSA)26Sortm38(CAG-GCaMP3)Hze/J (referred to as αMHC-Cre/Rosa26A-Flox-Stop-Flox-GCaMP3 below) mouse reporter line for cardiac reprogramming assessment. Neonatal cardiac fibroblasts (NCFs) isolated from the mouse strain are converted into induced cardiomyocytes (iCMs), allowing for convenient and efficient evaluation of reprogramming efficiency and functional maturation of iCMs via calcium (Ca2+) flux.
11:37
Cardiac Magnetic Resonance Imaging
0 Views •
2023
Source: Frederick W. Damen and Craig J. Goergen, Weldon School of Biomedical Engineering, Purdue University, West Lafayette, Indiana In this video, high field, small-bore magnetic resonance imaging (MRI) with physiological monitoring is demonstrated to acquire gated cine loops of the murine cardiovascular system. This procedure provides a basis for assessing left-ventricular function, visualizing vascular networks, and quantifying motion of organs due to respiration. Comparable small animal...
FAQs
Each method examines a different aspect of cardiac performance. Electrocardiography evaluates rhythm and conduction, echocardiography assesses chamber function and valve performance, and laboratory biomarkers can indicate myocardial injury. Symptoms and physical findings add clinical context, while other tests may further clarify structure or circulation. Combining these sources produces a more complete assessment than relying on one measurement alone.
Ventricular filling and ejection describe different phases of cardiac performance. Assessing both helps identify whether dysfunction relates to how the ventricle receives blood, how effectively it pumps, or both. This distinction contributes to evaluating severity and circulatory effects, supporting more specific characterization of heart failure, cardiomyopathy, or other conditions affecting myocardial function.
Timing and comparison are central to this distinction. Clinicians interpret current symptoms, findings, test results, and disease severity alongside prior measurements when available. Repeated assessments can reveal whether cardiac abnormalities are newly developing, persistent, or changing over time. This temporal perspective helps separate acute deterioration from established chronic dysfunction and informs subsequent management decisions.
The assessment can identify several clinically important abnormalities, including disturbed rhythm or conduction, impaired chamber function, abnormal valve performance, myocardial injury, and altered ventricular filling or ejection. These findings may point toward different causes of circulatory impairment, such as ischemia, cardiomyopathy, heart failure, or arrhythmia, rather than treating all cardiac dysfunction as the same process.
Evaluation begins with symptoms and physical findings, followed by targeted testing based on the clinical question. Electrocardiography examines rhythm and conduction, echocardiography evaluates structure and performance, and laboratory biomarkers provide additional information about myocardial injury. Other tests may be added when needed. Clinicians then integrate the results to determine severity, cause, and circulatory impact.
Repeated measurements are useful when clinicians need to track disease progression, treatment response, or changing severity. Comparing results over time can show whether cardiac performance is improving, remaining stable, or worsening. This monitoring also supports prognostic assessment and may reveal when a patient’s condition has changed enough to prompt consideration of advanced intervention.
Findings from the assessment help clinicians connect a patient’s symptoms and circulatory effects with an underlying cardiac problem. The resulting information supports treatment selection and provides a basis for estimating prognosis. Serial results add further value by showing response to therapy and identifying patients whose persistent or worsening dysfunction may require advanced intervention.
The approach supports evaluation of heart failure, ischemia, cardiomyopathy, and arrhythmias. Its value comes from combining clinical findings with information about electrical activity, chamber performance, valves, myocardial injury, and ventricular mechanics. This broader view helps clinicians characterize the cardiac abnormality, assess its severity, and distinguish conditions that may produce overlapping symptoms or circulatory impairment.